Soligenix Inc. (SNGX) Reports Promising HyBryte Results for CTCL Treatment
TL;DR
Soligenix's HyBryte(TM) shows a 75% success rate in early-stage CTCL treatment, offering a competitive edge in biopharmaceutical innovations for rare diseases.
HyBryte(TM) treatment for CTCL demonstrated 75% efficacy at 18 weeks, with safety and tolerability confirmed in an ongoing open-label study mirroring the FLASH2 trial design.
HyBryte(TM) provides a safer, faster-acting treatment for CTCL, improving patient outcomes and addressing the urgent need for new therapies in this underserved area.
Discover how Soligenix's HyBryte(TM) is revolutionizing CTCL treatment with an 85% improvement rate, offering hope through its non-mutagenic mechanism and rapid response.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix Inc. (SNGX) has shared encouraging interim data from a study on HyBryte(TM), a synthetic hypericin treatment for early-stage cutaneous T-cell lymphoma (CTCL), in a recent podcast by the Cutaneous Lymphoma Foundation. Dr. Ellen Kim, the study's Principal Investigator, reported a 75% treatment success rate at 18 weeks, with improvements reaching up to 85% in patients treated through 54 weeks. This study, mirroring the design of the ongoing FLASH2 confirmatory trial, builds on previous Phase 3 FLASH trial results and is noted for its real-world clinical practice approach, eliminating rest periods and extending treatment duration to enhance efficacy.
Dr. Kim highlighted HyBryte's safety and tolerability, with no serious side effects reported and only one dropout due to logistical reasons. The treatment's non-mutagenic mechanism and rapid response time position it as a potentially safer and more effective alternative to traditional CTCL treatments like steroids, chemotherapy, and phototherapy. This development is particularly significant for patients with early-stage CTCL, a chronic and underserved cancer, offering new hope where current skin-directed therapies fall short.
The progress of HyBryte underscores the urgent need for innovative treatments in the CTCL space, with Soligenix Inc. moving closer to potential commercialization following successful Phase 3 study completions. The company's focus on rare diseases with unmet medical needs is evident in its pipeline, which includes treatments for psoriasis, inflammatory diseases, and vaccine candidates for ricin toxin, filoviruses, and COVID-19, supported by government grants and contracts.
Curated from InvestorBrandNetwork (IBN)
